This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics Shares Fall On Drug Development Delay

NEW YORK (AP) ¿ Shares of Cytokinetics Inc. plunged Thursday after the biotechnology company said development of a potential heart failure drug could take a year longer than previously anticipated.

The stock slid 76 cents, or 17.8 percent, to $3.51 in afternoon trading. Shares have traded between $1.38 and $5.55 over the last 52 weeks.

Late Wednesday, the company said it agreed with partner Amgen Inc. on conducting additional mid-to-late-stage studies on omecamtiv mecarbil for heart failure and renal dysfunction patients in 2011.

Lazard Capital Markets analyst Joel Sendek reaffirmed a "Buy" rating on Cytokinetics, but said the delayed timeline could affect milestone payments to Cytokinetics.

Cytokinetics also said its third-quarter loss narrowed on more revenue from collaborations.

The company recorded a loss of $8.2 million, or 14 cents per share, compared with a loss of $16.3 million, or 33 cents per share, during the same period a year prior. Revenue rose 76 percent to $5.5 million from $3.1 million.

Analysts polled by Thomson Reuters expected a loss of 22 cents per share on revenue of $2.9 million.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $154.17 -1.40%
CYTK $8.14 -3.10%
AAPL $94.19 -1.04%
FB $118.08 0.55%
GOOG $695.81 0.50%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs